Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17070332 | 0.85 | L3MBTL1 (0.52) | L3MBTL1HCAR2KEAP1NFE2L2ATM | |
| SCHEMBL15490808 | 0.84 | L3MBTL1 (0.52) | L3MBTL1HCAR2KEAP1NFE2L2ATM | |
| SCHEMBL2609709 | 0.83 | GAA (0.43) | L3MBTL1HCAR2KEAP1NFE2L2ATM | |
| SCHEMBL2609702 | 0.83 | ALDH1A1 (0.42) | L3MBTL1HCAR2KEAP1NFE2L2ATM | |
| SCHEMBL2609692 | 0.81 | L3MBTL1 (0.54) | L3MBTL1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL19710848 | 0.79 | L3MBTL1 (0.44) | L3MBTL1HCAR2KEAP1NFE2L2TDP1 | |
| SCHEMBL2190802 | 0.78 | ALDH1A1 (0.53) | HCAR2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL2190798 | 0.78 | ALDH1A1 (0.53) | HCAR2KEAP1NFE2L2KDM4EALDH1A1 | |
| SCHEMBL2904241 | 0.76 | TPSAB1 (0.49) | TPSAB1TPSD1TPSG1L3MBTL1KDM4E | |
| SCHEMBL2904236 | 0.76 | TPSAB1 (0.49) | TPSAB1TPSD1TPSG1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11903918-B2 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | BANNER LIFE SCIENCES LLC (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4215191-A1 | COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11590095-B2 | Fumarate ester dosage forms | BANNER LIFE SCIENCES LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3804711-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10959972-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | TPSAB1 2989/4885TPSD1 2583/4885TPSG1 1948/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | TPSAB1 3260/4885TPSD1 2656/4885TPSG1 2433/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | TPSAB1 2989/4885TPSD1 2583/4885TPSG1 1948/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | TPSAB1 3416/4885TPSD1 2757/4885TPSG1 2348/4885 |
| US-11590095-B2 | Fumarate ester dosage forms | FH, FAH, SDHB | TPSAB1 3892/4885TPSD1 3240/4885TPSG1 3984/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | TPSAB1 2989/4885TPSD1 2583/4885TPSG1 1948/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | TPSAB1 2989/4885TPSD1 2583/4885TPSG1 1948/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | TPSAB1 2989/4885TPSD1 2583/4885TPSG1 1948/4885 |
| US-10959972-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | TPSAB1 2989/4885TPSD1 2583/4885TPSG1 1948/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | TPSAB1 3260/4885TPSD1 2656/4885TPSG1 2433/4885 |
| US-11903918-B2 | Fumarate ester dosage forms with enhanced gastrointestinal tolerability | FH, SI, FAH | TPSAB1 2548/4885TPSD1 1423/4885TPSG1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.